Every 8-K that Penumbra Inc (PEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PEN filings page.
Penumbra, Inc. reported revenue of $390.0 million for the second quarter ended June 30, 2026, an increase of 14.9% compared with the second quarter of 2025. Global thrombectomy revenue was $259.0 million and global embolization and access revenue was $131.1 million.
Gross profit margin was 67.9%. Total operating expenses were $223.9 million, including $25.4 million of research and development and $198.5 million of sales, general and administrative expense, with $6.9 million related to the pending acquisition by Boston Scientific Corporation. Income from operations was $41.0 million and net income was $34.8 million. Because of the pending acquisition, the company will not provide full-year 2026 financial guidance or host a conference call to discuss these results.
Revenue growth included 17.1% growth in the United States and 7.6% growth internationally. By product category, thrombectomy revenue grew 12.5% and embolization and access revenue grew 20.0% compared with the second quarter of 2025.
Penumbra, Inc. held its Annual Meeting of Stockholders on June 18, 2026.
Stockholders elected directors Arani Bose, M.D., Bridget O'Rourke, and Surbhi Sarna, who received 21,137,932 to 24,232,264 votes For. A second proposal received 29,208,244 votes For, and a third received 24,113,038 votes For.
Out of 39,331,425 shares outstanding and entitled to vote as of April 22, 2026, 29,260,683 shares were represented in person or by proxy at the meeting.
Penumbra, Inc. stockholders approved all three merger-related proposals at a special meeting held on May 6, 2026, satisfying the key condition that the Merger Agreement be adopted by a majority of outstanding shares.
The company had 39,324,084 shares entitled to vote as of March 26, 2026, with 28,665,933 shares represented at the meeting, forming a quorum. The proposals each received strong support, including one with 28,564,786 votes for, 85,334 against, and 15,813 abstentions. Completion of the merger still depends on remaining closing conditions, including expiration or termination of the Hart-Scott-Rodino waiting period and clearances under certain non-U.S. antitrust, competition, or foreign investment laws.
Penumbra, Inc. reported first quarter 2026 revenue of $374.8 million, up 15.6% from the first quarter of 2025, driven by growth in both thrombectomy and embolization businesses. Global thrombectomy revenue was $253.9 million, up 12.1%, while embolization and access revenue reached $120.8 million, up 23.8%.
Gross profit margin improved to 67.6%, but net income declined to $32.6 million from $39.2 million, reflecting higher operating expenses of $215.2 million, including $9.4 million of acquisition-related expenses tied to the pending acquisition by Boston Scientific Corporation. Diluted earnings per share were $0.82 versus $1.00 a year earlier.
Cash and cash equivalents were $241.3 million and marketable investments were $374.4 million as of March 31, 2026, supporting a total asset base of $1.90 billion. Given the pending acquisition by Boston Scientific, Penumbra is not providing full-year 2026 financial guidance and is not hosting a conference call for this quarter.
Penumbra, Inc. reported strong growth for the fourth quarter and full year 2025, highlighted by rising revenue and improved profitability. Fourth quarter revenue reached $385.4 million, up 22.1% from a year earlier, with net income of $47.3 million and an adjusted EBITDA margin of 20.5%.
For 2025, revenue grew to $1,403.7 million, an increase of 17.5%, while net income climbed to $177.7 million, or $4.52 per diluted share, and adjusted EBITDA was $266.8 million with a 19.0% margin. Thrombectomy and embolization products both delivered double-digit growth. Because of the proposed acquisition of Penumbra by Boston Scientific Corporation, the company is not providing 2026 guidance and will not host a conference call.
Penumbra, Inc. agreed to be acquired by Boston Scientific Corporation through a cash-and-stock merger where Penumbra will become a wholly owned subsidiary. At closing, each Penumbra common share will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific common shares, with elections subject to proration so that approximately 73.26% of shares receive cash and 26.74% receive stock.
The deal requires approval by a majority of Penumbra’s voting shares, antitrust and other regulatory clearances, effectiveness of Boston Scientific’s Form S-4, and NYSE listing approval for the stock consideration. Either side may owe a termination fee under certain conditions, including $525 million payable by Penumbra and $900 million payable by Boston Scientific if specified antitrust-related conditions are not met. If the merger closes, Penumbra’s stock will be delisted and deregistered, and the companies have issued and plan further SEC filings and proxy materials describing the transaction.
Penumbra, Inc. furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated into other filings unless specifically referenced. The report was signed by CFO Maggie Yuen on November 5, 2025.
Penumbra, Inc. appointed Ms. Narayan as President and approved related compensation and disclosure. The company disclosed that Ms. Narayan’s spouse is Founder and CEO of N28 Technologies, an IT service provider that has provided services to Penumbra under commercial agreements totaling approximately $2 million since January 1, 2024. Those transactions were reviewed and approved by the Nominating and Corporate Governance Committee under the company’s Related Person Transaction Policy. In connection with her appointment, the Compensation Committee approved a grant of restricted stock units valued at approximately $2.5 million, effective September 15, 2025, vesting in equal annual installments over four years subject to continued service. Adam Elsesser will remain Chairman and Chief Executive Officer.